{"id":45225,"date":"2022-06-17T17:01:31","date_gmt":"2022-06-17T15:01:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-rna-therapeutics-market-trends-growth-drivers-and-growth-opportunities-2021-2022-2027-researchandmarkets-com\/"},"modified":"2022-06-17T17:01:31","modified_gmt":"2022-06-17T15:01:31","slug":"global-rna-therapeutics-market-trends-growth-drivers-and-growth-opportunities-2021-2022-2027-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-rna-therapeutics-market-trends-growth-drivers-and-growth-opportunities-2021-2022-2027-researchandmarkets-com\/","title":{"rendered":"Global RNA Therapeutics Market Trends, Growth Drivers, and Growth Opportunities 2021-2022 & 2027 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global RNA Therapeutics Growth Opportunities”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis research service provides an overview of the global RNA therapeutics industry from 2021 to 2027, including emerging trends, growth drivers, and growth opportunities.\n<\/p>\n

\nScientific advancements in nucleic acid-based therapies have significantly impacted the global biopharmaceutical industry. The ribonucleic acid (RNA) therapeutics market is expected to witness remarkable clinical progress as therapies target “undruggable” pathways.\n<\/p>\n

\nTechnologically advanced platforms are integrated into RNA therapeutics bioprocessing to overcome stability issues. Technological advantages, coupled with the growing need to build clinically superior portfolios in RNA therapeutics for a competitive edge, are anticipated to drive strategic partnerships among stakeholders in the RNA therapeutics industry.\n<\/p>\n

\nSpurred by the COVID-19 pandemic, biopharmaceutical companies are likely to prioritize microRNA, small interfering RNA, and antisense oligonucleotides as promising therapeutic modalities during the forecast period. Midsize and large companies have ramped up the production of starting materials and the final formulation of RNA therapeutics, which is likely to propel stakeholders to seek synergistic partnerships.\n<\/p>\n

\nIn the industry’s transition to personalized therapeutics, RNA developers are capitalizing on the high precision of RNA to treat untapped chronic disease areas such as cystic fibrosis, solid tumors, and spinal muscular atrophy. They engage in co-development programs to improve the stability profile of RNA therapeutics by optimizing drug delivery carriers, such as lipid nanoparticles.\n<\/p>\n

\nScaling up the production of starting materials, including plasmid DNA, oligonucleotides, and delivery materials, to ensure continuous manufacturing is anticipated to reduce the operational timeframe of RNA therapeutics production. Technology transfer and the outsourcing of crucial operations to contract development and manufacturing organizations (CDMO) catalyze the development of cost-effective and efficient models for RNA therapeutics.\n<\/p>\n

\nThe research service highlights the following:<\/strong>\n<\/p>\n